Call Options

16 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

SELL
$171.37 - $283.23 $2.12 Million - $3.51 Million
-12,400 Reduced 90.51%
1,300 $347,000
Q4 2023

Feb 14, 2024

SELL
$120.4 - $237.13 $337,120 - $663,964
-2,800 Reduced 16.97%
13,700 $3.17 Million
Q3 2023

Nov 14, 2023

BUY
$146.04 - $225.78 $511,140 - $790,230
3,500 Added 26.92%
16,500 $2.41 Million
Q2 2023

Aug 14, 2023

SELL
$203.88 - $312.0 $142,716 - $218,400
-700 Reduced 5.11%
13,000 $3 Million
Q1 2023

May 15, 2023

BUY
$231.06 - $307.08 $1.27 Million - $1.69 Million
5,500 Added 67.07%
13,700 $3.32 Million
Q4 2022

Feb 14, 2023

SELL
$58.39 - $296.54 $397,052 - $2.02 Million
-6,800 Reduced 45.33%
8,200 $2.38 Million
Q3 2022

Nov 14, 2022

BUY
$60.57 - $79.51 $399,762 - $524,766
6,600 Added 78.57%
15,000 $975,000
Q2 2022

Aug 08, 2022

BUY
$58.04 - $100.2 $487,536 - $841,680
8,400 New
8,400 $601,000
Q4 2020

Feb 16, 2021

SELL
$110.06 - $133.7 $792,432 - $962,639
-7,200 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$99.78 - $124.21 $1.69 Million - $2.1 Million
-16,900 Reduced 70.12%
7,200 $855,000
Q2 2020

Aug 14, 2020

BUY
$60.13 - $125.71 $1.45 Million - $3.03 Million
24,100 New
24,100 $2.73 Million
Q1 2020

May 15, 2020

SELL
$66.76 - $93.49 $360,504 - $504,846
-5,400 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$84.28 - $118.5 $455,112 - $639,900
5,400 New
5,400 $492,000
Q3 2019

Nov 14, 2019

SELL
$84.4 - $106.53 $970,600 - $1.23 Million
-11,500 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$91.13 - $142.5 $328,068 - $513,000
3,600 Added 45.57%
11,500 $1.21 Million
Q1 2019

May 15, 2019

BUY
$103.48 - $143.84 $817,492 - $1.14 Million
7,900 New
7,900 $990,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.37B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Walleye Trading LLC Portfolio

Follow Walleye Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.